Answers to burning questions for clinical allergologists related to the new COVID-19 vaccines
Tóm tắt
Along with the newly approved vaccines against coronavirus disease 2019 (COVID-19), first reports of allergic or intolerance reactions were published. Subsequently, questions arose whether these vaccines pose an increased risk for intolerance reactions and whether allergic patients may be at higher risk for this. Allergic reactions following COVID-19 vaccinations have been reported, but mostly of mild severity and at normal (Moderna®) or only slightly increased frequency (BioNTech/Pfizer®) compared to established conventional vaccines. The risk of allergic reaction to the newly licensed vector vaccines (AstraZeneca®, Johnson&Johnson®) cannot be conclusively assessed yet, but also appears to be low. There is currently no evidence that patients with allergic diseases (atopic patients) react more frequently or more severely to these vaccines. It is currently assumed that intolerance reactions of the immediate-type are either type I allergic (IgE-mediated) reactions or occur via complement activation (CARPA, “complement activation-related pseudoallergy”). Polyethylene glycol (PEG) or polysorbate, which are present as stabilizers in the vaccines, are suspected as triggers for this. The data available so far do not show a significantly increased risk of immediate-type allergic reactions in atopic persons. In almost all cases, atopic patients can be vaccinated without problems. Standardized follow-up tests after suspected allergic reactions or CARPA-mediated reactions are currently limited.
Tài liệu tham khảo
WHO. Landscapes of COVID-19 candiate vaccines. 2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed 29 Jan 2021.
MHRA. MHRA public assessment report—Authorisation for temporary supply COVID-19 mRNA vaccine BNT162b2 (BNT162b2 RNA) concentrate for solution for injection.. https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19 (Created 11 Dec 2020). Accessed 17 Dec 2020.
Inglut CT, Sorrin AJ, Kuruppu T, Vig S, Cicalo J, Ahmad H, et al. Immunological and toxicological considerations for the design of liposomes. Nanomater (Basel). 2020;10:190.
Calogiuri G, Foti C, Nettis E, Di Leo E, Macchia L, Vacca A. Polyethylene glycols and polysorbates: Two still neglected ingredients causing true IgE-mediated reactions. J Allergy Clin Immunol Pract. 2019;7:2509–10.
Giavina-Bianchi P, Kalil J. Polyethylene glycol is a cause of IgE-mediated anaphylaxis. J Allergy Clin Immunol Pract. 2019;7:1874–5.
Stone CA Jr., Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 2019;7:1533–1540.e8.
Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. 2016;46:907–22.
Wylon K, Dolle S, Worm M. Polyethylene glycol as a cause of anaphylaxis. Allergy Asthma Clin Immunol. 2016;12:67.
American Society for Dermatologic Surgery. Guidance regarding SARS-CoV‑2 mRNA vaccine side effects in dermal filler patients—Based on information available as of 28 December 2020. 2020. https://www.asds.net/Portals/0/PDF/secure/ASDS-SARS-CoV-2-Vaccine-Guidance.pdf. Accessed 12 Feb 2021.
Szebeni J, Muggia F, Gabizon A, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev. 2011;63:1020–30.
Mohamed M, Abu Lila AS, Shimizu T, Alaaeldin E, Hussein A, Sarhan HA, et al. PEGylated liposomes: immunological responses. Sci Technol Adv Mater. 2019;20:710–24.
CDC COVID-19 Response Team, Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine—United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70:46–51.
Shimabukuro T. COVID-19 vaccine safety update—January 27, 2021. National Center for Immunization and Respiratory Diseases—Advisory Comittee on Immunozation Pracitices (ACIP). 2021. www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-01/06-COVID-Shimabukuro.pdf. Accessed 12 Feb 2021.
Ruggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25:5675–84.
European Medicines Agency. EudraVigilance—European database of suspected adverse drug reactions. 2021. https://www.adrreports.eu/de/search_subst.html. Accessed 15 Apr 2021.
Berkeley LJ. J&J says two trial participants had severe allergic reactions after getting Covid vaccine. CNBC. 2021. www.cnbc.com/2021/02/26/jj-says-two-people-had-severe-allergic-reactions-after-getting-covid-vaccine.html. Accessed 17 Mar 2021.
CDC. Local reactions, systemic reactions, adverse events, and serious adverse events: Janssen COVID-19 vaccine. 2021. www.cdc.gov/vaccines/covid-19/info-by-product/janssen/reactogenicity.html. Accessed 17 Mar 2021.
Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146:110–8.
Doessegger L, Banholzer ML. Clinical development methodology for infusion-related reactions with monoclonal antibodies. Clin Transl Immunology. 2015;4:e39.
Klimek L, Pfaar O, Worm M, Eiwegger T, Hagemann J, Ollert M, et al. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemie: Positionspapier des Ärzteverbands Deutscher Allergologen (AeDA)A, der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI)B, der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI)D, der Luxemburgischen Gesellschaft für Allergologie und Immunologie (LGAI)E, der Österreichischen Gesellschaft für Pneumologie (OGP)F in Kooperation mit der deutschen, österreichischen und schweizerischen ARIA-GruppeG und der Europäischen Akademie für Allergologie und Klinische Immunologie (EAACI)H. Allergo J 2020;29(4):14–27.
Klimek L, Pfaar O, Worm M, Bergmann KC, Bieber T, Buhl R, et al. Allergen-Immuntherapie in der aktuellen Covid-19-Pandemie: Positionspapier der deutschen ARIA-GruppeA in Kooperation mit der österreichischen ARIA-GruppeB, der schweizerischen ARIA-GruppeC, dem Ärzteverband Deutscher Allergologen (AeDA)D, der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI)E und der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)F in Kooperation mit der AG Klinische Immunologie, Allergologie und Umweltmedizin der DGHNO-KHCG und der Europäischen Akademie für Allergologie und klinische Immunologie (EAACI)H. Allergo J 2020;29(3):17–25.
Sellaturay P, Nasser S, Ewan P. Polyethylene glycol-induced systemic allergic reactions (anaphylaxis). J Allergy Clin Immunol Pract. 2021;9:670–5.
CDC. Interim considerations: Preparing for the potential management of anaphylaxis after COVID-19 vaccination.. www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html (Created 10 Feb 2021). Accessed 12 Feb 2021.
Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy. 2021; https://doi.org/10.1111/all.14739.
Castells MC, Phillips EJ. Maintaining safety with SARS-CoV‑2 vaccines. N Engl J Med. 2020; https://doi.org/10.1056/NEJMra2035343.